Description
Indication & Scope
LvMingCe® Relmapirazin Injection is used together with MediBeacon transdermal glomerular filtration rate measuring device to quantitatively evaluate patient glomerular filtration rate for renal function staging.
- Mechanism: Relmapirazin is a fluorescent renal tracer agent with exclusive glomerular filtration elimination pathway. After intravenous injection, it freely passes through renal glomeruli without tubular reabsorption or secretion. Transdermal optical equipment detects real-time blood tracer concentration decay to calculate accurate GFR values.
- Drug class: Fluorescent diagnostic tracer; injectable renal function contrast agent.
- Clinical use: In-vivo diagnostic testing for accurate glomerular filtration rate quantification; guides chronic kidney disease staging and renal medication dose adjustment.
| Generic Name | Relmapirazin Injection |
| Brand Name | LvMingCe |
| Ingredient | Relmapirazin |
| Dosage Form | Injection |
| Package | 7ml: 130.2mg*1 vial/box |
| Conditions Treated | Diagnostic evaluation of glomerular filtration rate in patients with suspected or confirmed chronic kidney disease |
| Taboos | Severe hypersensitivity to fluorescent tracer agents or injection solution excipients; patients with complete anuria end-stage renal failure |
| Place of origin | China |
| Prescription type | Prescription-only |
| Storage Conditions | Refrigerate unopened ampoules at 2°C–8°C, protect from intense visible and ultraviolet light. Do not freeze the liquid formulation |
| Manufacturer | ZhongMeiHuaDong Pharmaceytical, Ltd. |
| Registration Authority | National Medical Products Administration (NMPA), China |
| Approval number | H20250060 |
| Approval Date | Oct 14, 2025 |
| Shelf Life | 24 months |
How to use ?
Recommended Dose: Standard fixed volume intravenous injection calibrated to patient body surface area, per device diagnostic kit guidelines.
Time: Single bolus intravenous injection completed before transdermal GFR measurement scan procedure.
Instructions for use: Administer via peripheral vein bolus injection; ensure no extravasation during infusion. Complete GFR reading procedure within 60 minutes post-injection.
Interaction: Photosensitizing pharmaceutical agents interfere with transdermal fluorescent signal detection and should be withheld before testing.
Side effects:
1. Mild common reactions: transient injection site redness, mild headache.
2. Severe rare adverse events: anaphylactic hypersensitivity reaction, transient hypotension.
Important Notice
This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indicatiaon, and regional regulatory requirements.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
What is the core clinical function of Relmapirazin Injection?
It is used to quantitatively evaluate glomerular filtration rate and assist in staging chronic kidney disease.
What is the dosage form of Relmapirazin Injection?
It is a sterile single-use aqueous solution for intravenous injection.
Which patients are prohibited from using Relmapirazin Injection?
Patients with severe tracer hypersensitivity and end-stage renal failure with complete anuria are contraindicated.
What drugs will interfere with Relmapirazin Injection's diagnostic effect?
Photosensitizing drugs will interfere with fluorescent signal detection and affect accurate GFR measurement.
LvMingCe® | Relmapirazin Injection | Evaluation of GFR | DengYueRX
INN: Relmapirazin Injection
Indications: Evaluation of glomerular filtration rate (GFR)
Dosage Form: Injection
Strength: 7ml: 130.2mg/vial
Low MOQ
WHO-GMP
Worldwide Delivery
Compliance and Regulatory Documents
Related Products
